In-Med Prognostics, a Pune-based AI company with expertise in multi-modal data and image processing, has raised $2.13M to stabilize and expand the product portfolio and tap global markets.

The company leverages deep learning algorithms and machine learning to provide accurate neuro analysis which aids early detection of neurological disorders such as Dementia, Alzheimer’s, and Parkinson’s at affordable prices. Its ‘Neuroshield’ solution provides a self-explanatory volumetric report within 20 minutes.

Speaking about the significance of the investment, Dr. Latha Poonamallee, co-founder, In-Med Prognostics, said: “We are beyond thrilled about putting this investment to good use and strengthen and broaden our product suite and go further in our mission to bring accessible state of the art AI based healthcare tools to the emerging world and beyond.”

Rajesh Purushottam, co-founder, In-Med Prognostics also said that the investment pivots them to develop some cutting-edge solutions as part of their innovation funnel in the neurosciences space and deliver in both volume and value markets.

In India, In-Med is already working with Aarthi Scans, Scansworld, Gujarat Scans, Nanavati, and Cauvery hospitals. The company is also expanding to Africa and is targeting a global multi-billion diagnostic and wellness market.

Author

Arushi Soni

Arushi works as a Writer for HealthLEADS. She holds a bachelor's degree in English Literature from Shiv Nadar University. Her previous experience includes roles as a Writer and Reporter for The Hindu and Firstpost, Network18.
View all posts